FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229013468> ?p ?o ?g. }

• W4229013468 abstract "Abstract Background Monitoring proteinuria is important for the management of patients with cancer treated with anti-vascular endothelial growth factor (VEGF) or anti-VEGF receptor (VEGFR) inhibitors (VEGF/Ri). Here we investigated the difference between the urine protein/creatinine ratio (UPCR) and a qualitative value test (QV) on the decision making of treatment continuation and the usefulness of UPCR testing in patients with gastrointestinal cancer treated with anti-VEGF/Ri. Methods From January 2017 to December 2018, a survey was conducted based on the medical records of patients with gastrointestinal cancer with a QV of ≥2+ during the use of anti-VEGF/Ri at seven Japanese institutions participating in the Onco-nephrology Consortium. The primary endpoint was the ratio of the worst UPCR < 2.0 (low UPCR) in cases with a QV2+ at the point of the first proteinuria onset. The secondary endpoints were a comparison of low UPCR and worst UPCR ≥2.0 (high UPCR), the concordance rate between UPCR and QV in the Common Terminology Criteria for Adverse Events (CTCAE) grading, and the differences in the decision making for anti-VEGF/Ri continuation. Results Among the 71 patients enrolled, the proportion of low UPCR in onset QV2+ ( n = 53) was 66% ( n = 35). In a comparison between low ( n = 36) and high UPCR cases ( n = 24), body weight ( P = 0.036), onset QV status ( P = 0.0134), and worst QV status ( P < 0.0001) were significantly associated with UPCR levels. The concordance rate for CTCAE Grade 2 of both the QV and UPCR was 83%. Regarding the judgment of anti-VEGF/Ri continuation, treatment was continued in 42.4% of cases when the QV became 3+, whereas only 25% continued treatment when the UPCR value became high. Conclusion Urine dipstick test results may overestimate proteinuria, and the UPCR result tended to be more critical than the QV when deciding the treatment policy. Trial registration This study is a multiple institutional retrospectively registered observational trial. Clinical Trial number: University Hospital Medical Information Network (UMIN) Clinical Trials Registry (protocol ID UMIN000042545 )." @default.
• W4229013468 created "2022-05-08" @default.
• W4229013468 creator A5007007321 @default.
• W4229013468 creator A5016535461 @default.
• W4229013468 creator A5020808188 @default.
• W4229013468 creator A5022854492 @default.
• W4229013468 creator A5024787748 @default.
• W4229013468 creator A5033052103 @default.
• W4229013468 creator A5041684090 @default.
• W4229013468 creator A5045950776 @default.
• W4229013468 creator A5053240410 @default.
• W4229013468 creator A5058445735 @default.
• W4229013468 creator A5064363130 @default.
• W4229013468 creator A5072512404 @default.
• W4229013468 creator A5075964384 @default.
• W4229013468 creator A5084128352 @default.
• W4229013468 creator A5084965625 @default.
• W4229013468 date "2022-05-07" @default.
• W4229013468 modified "2023-10-12" @default.
• W4229013468 title "Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study)" @default.
• W4229013468 cites W1764548635 @default.
• W4229013468 cites W2111237964 @default.
• W4229013468 cites W2115735904 @default.
• W4229013468 cites W2121847974 @default.
• W4229013468 cites W2135626946 @default.
• W4229013468 cites W2143743735 @default.
• W4229013468 cites W2144554119 @default.
• W4229013468 cites W2152575748 @default.
• W4229013468 cites W2165388519 @default.
• W4229013468 cites W2775857678 @default.
• W4229013468 cites W2954340933 @default.
• W4229013468 cites W3018368958 @default.
• W4229013468 cites W3089594756 @default.
• W4229013468 cites W3135368288 @default.
• W4229013468 cites W3163023941 @default.
• W4229013468 doi "https://doi.org/10.1186/s12885-022-09611-3" @default.
• W4229013468 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35525917" @default.
• W4229013468 hasPublicationYear "2022" @default.
• W4229013468 type Work @default.
• W4229013468 citedByCount "2" @default.
• W4229013468 countsByYear W42290134682023 @default.
• W4229013468 crossrefType "journal-article" @default.
• W4229013468 hasAuthorship W4229013468A5007007321 @default.
• W4229013468 hasAuthorship W4229013468A5016535461 @default.
• W4229013468 hasAuthorship W4229013468A5020808188 @default.
• W4229013468 hasAuthorship W4229013468A5022854492 @default.
• W4229013468 hasAuthorship W4229013468A5024787748 @default.
• W4229013468 hasAuthorship W4229013468A5033052103 @default.
• W4229013468 hasAuthorship W4229013468A5041684090 @default.
• W4229013468 hasAuthorship W4229013468A5045950776 @default.
• W4229013468 hasAuthorship W4229013468A5053240410 @default.
• W4229013468 hasAuthorship W4229013468A5058445735 @default.
• W4229013468 hasAuthorship W4229013468A5064363130 @default.
• W4229013468 hasAuthorship W4229013468A5072512404 @default.
• W4229013468 hasAuthorship W4229013468A5075964384 @default.
• W4229013468 hasAuthorship W4229013468A5084128352 @default.
• W4229013468 hasAuthorship W4229013468A5084965625 @default.
• W4229013468 hasBestOaLocation W42290134681 @default.
• W4229013468 hasConcept C126322002 @default.
• W4229013468 hasConcept C126894567 @default.
• W4229013468 hasConcept C141071460 @default.
• W4229013468 hasConcept C160798450 @default.
• W4229013468 hasConcept C167734588 @default.
• W4229013468 hasConcept C2779513377 @default.
• W4229013468 hasConcept C2779561371 @default.
• W4229013468 hasConcept C2780091579 @default.
• W4229013468 hasConcept C2780140570 @default.
• W4229013468 hasConcept C2780306776 @default.
• W4229013468 hasConcept C71924100 @default.
• W4229013468 hasConceptScore W4229013468C126322002 @default.
• W4229013468 hasConceptScore W4229013468C126894567 @default.
• W4229013468 hasConceptScore W4229013468C141071460 @default.
• W4229013468 hasConceptScore W4229013468C160798450 @default.
• W4229013468 hasConceptScore W4229013468C167734588 @default.
• W4229013468 hasConceptScore W4229013468C2779513377 @default.
• W4229013468 hasConceptScore W4229013468C2779561371 @default.
• W4229013468 hasConceptScore W4229013468C2780091579 @default.
• W4229013468 hasConceptScore W4229013468C2780140570 @default.
• W4229013468 hasConceptScore W4229013468C2780306776 @default.
• W4229013468 hasConceptScore W4229013468C71924100 @default.
• W4229013468 hasIssue "1" @default.
• W4229013468 hasLocation W42290134681 @default.
• W4229013468 hasLocation W42290134682 @default.
• W4229013468 hasLocation W42290134683 @default.
• W4229013468 hasLocation W42290134684 @default.
• W4229013468 hasOpenAccess W4229013468 @default.
• W4229013468 hasPrimaryLocation W42290134681 @default.
• W4229013468 hasRelatedWork W165857015 @default.
• W4229013468 hasRelatedWork W1991863845 @default.
• W4229013468 hasRelatedWork W2019256992 @default.
• W4229013468 hasRelatedWork W2129198067 @default.
• W4229013468 hasRelatedWork W2743225796 @default.
• W4229013468 hasRelatedWork W2916219914 @default.
• W4229013468 hasRelatedWork W3148712325 @default.
• W4229013468 hasRelatedWork W3155340504 @default.
• W4229013468 hasRelatedWork W593504957 @default.
• W4229013468 hasRelatedWork W2088864129 @default.
• W4229013468 hasVolume "22" @default.
• W4229013468 isParatext "false" @default.
• W4229013468 isRetracted "false" @default.

• next